PLUS1
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 0.72 ▼ -0.01 (-1.76%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ocugen Inc | OCGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.0313 | 4.49% | 0.7278 | 0.8388 | 0.71 | 0.73 | 0.6965 | 00:00:05 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.706 | 0.73 | 0.024 | 3.29% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 27,320 | 21,466,353 | $ 0.7879487 | $ 16,914,385 | 8,851,913 | 0.235 - 3.35 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:40 | 8 | $ 0.715 | USD |
Ocugen Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 38.30M | 52.63M | -60.00 | - | 51.84M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Ocugen News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/03/2020 | 16:47 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/31/2019 | 16:12 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/20/2019 | 16:47 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 12/18/2019 | 11:13 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/16/2019 | 17:10 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 12/16/2019 | 17:00 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 12/16/2019 | 16:56 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OCGN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.675 | 0.8388 | 0.562 | 0.6499811 | 6,719,858 | 0.0528 | 7.82% |
| 1 Month | 0.38 | 0.8388 | 0.37 | 0.5729116 | 9,280,708 | 0.3478 | 91.53% |
| 3 Months | 1.90 | 1.91 | 0.235 | 0.4897576 | 7,283,656 | -1.17 | -61.69% |
| 6 Months | 3.24 | 3.35 | 0.235 | 0.6566521 | 6,223,366 | -2.51 | -77.54% |
| 1 Year | 3.24 | 3.35 | 0.235 | 0.6566521 | 6,223,366 | -2.51 | -77.54% |
| 3 Years | 3.24 | 3.35 | 0.235 | 0.6566521 | 6,223,366 | -2.51 | -77.54% |
| 5 Years | 3.24 | 3.35 | 0.235 | 0.6566521 | 6,223,366 | -2.51 | -77.54% |
Ocugen Description
| Ocugen Inc is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. |
